I think the FDA has now given a route-map to approval, and so subsequent entrants will have an easier time of it than MNTA did. The Amphastar disclosures added to my conviction on this.
It sounds like you don't regard MNTA's IP as an impediment. Also, which Amphastar disclosures are you referring to?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.